Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74


Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma.

Agemy L, Friedmann-Morvinski D, Kotamraju VR, Roth L, Sugahara KN, Girard OM, Mattrey RF, Verma IM, Ruoslahti E.

Proc Natl Acad Sci U S A. 2011 Oct 18;108(42):17450-5. doi: 10.1073/pnas.1114518108. Epub 2011 Oct 3. Erratum in: Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11906.


CREKA peptide-conjugated dendrimer nanoparticles for glioblastoma multiforme delivery.

Zhao J, Zhang B, Shen S, Chen J, Zhang Q, Jiang X, Pang Z.

J Colloid Interface Sci. 2015 Jul 15;450:396-403. doi: 10.1016/j.jcis.2015.03.019. Epub 2015 Mar 23.


MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma.

Costa PM, Cardoso AL, Custódia C, Cunha P, Pereira de Almeida L, Pedroso de Lima MC.

J Control Release. 2015 Jun 10;207:31-9. doi: 10.1016/j.jconrel.2015.04.002. Epub 2015 Apr 7.


Polyethylene glycol-polylactic acid nanoparticles modified with cysteine-arginine-glutamic acid-lysine-alanine fibrin-homing peptide for glioblastoma therapy by enhanced retention effect.

Wu J, Zhao J, Zhang B, Qian Y, Gao H, Yu Y, Wei Y, Yang Z, Jiang X, Pang Z.

Int J Nanomedicine. 2014 Nov 13;9:5261-71. doi: 10.2147/IJN.S72649. eCollection 2014.


RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.

Gao H, Xiong Y, Zhang S, Yang Z, Cao S, Jiang X.

Mol Pharm. 2014 Mar 3;11(3):1042-52. doi: 10.1021/mp400751g. Epub 2014 Feb 19.


Combination therapy targeting integrins reduces glioblastoma tumor growth through antiangiogenic and direct antitumor activity and leads to activation of the pro-proliferative prolactin pathway.

Oliveira-Ferrer L, Wellbrock J, Bartsch U, Penas EM, Hauschild J, Klokow M, Bokemeyer C, Fiedler W, Schuch G.

Mol Cancer. 2013 Nov 20;12(1):144. doi: 10.1186/1476-4598-12-144.


Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles.

Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG.

Oncotarget. 2015 Apr 20;6(11):8788-806.


Nanoparticle-Mediated Target Delivery of TRAIL as Gene Therapy for Glioblastoma.

Wang K, Kievit FM, Jeon M, Silber JR, Ellenbogen RG, Zhang M.

Adv Healthc Mater. 2015 Dec 9;4(17):2719-26. doi: 10.1002/adhm.201500563. Epub 2015 Oct 26.


Radiosensitivity enhancement of radioresistant glioblastoma by epidermal growth factor receptor antibody-conjugated iron-oxide nanoparticles.

Bouras A, Kaluzova M, Hadjipanayis CG.

J Neurooncol. 2015 Aug;124(1):13-22. doi: 10.1007/s11060-015-1807-0. Epub 2015 May 17.


Chimeric Mouse model to track the migration of bone marrow derived cells in glioblastoma following anti-angiogenic treatments.

Achyut BR, Shankar A, Iskander AS, Ara R, Knight RA, Scicli AG, Arbab AS.

Cancer Biol Ther. 2016;17(3):280-90. doi: 10.1080/15384047.2016.1139243. Epub 2016 Jan 21.


Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma.

Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG 2nd, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, Aldape KD, Fuller GN, Höök M, Gelovani JG, Sidman RL, Cavenee WK, Pasqualini R, Arap W.

J Clin Invest. 2011 Jan;121(1):161-73. doi: 10.1172/JCI44798. Epub 2010 Dec 22.


Proapoptotic peptide-mediated cancer therapy targeted to cell surface p32.

Agemy L, Kotamraju VR, Friedmann-Morvinski D, Sharma S, Sugahara KN, Ruoslahti E.

Mol Ther. 2013 Dec;21(12):2195-204. doi: 10.1038/mt.2013.191. Epub 2013 Aug 20. Erratum in: Mol Ther. 2014 Nov;22(11):2013.


A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment.

Zhang CX, Zhao WY, Liu L, Ju RJ, Mu LM, Zhao Y, Zeng F, Xie HJ, Yan Y, Lu WL.

Oncotarget. 2015 Oct 20;6(32):32681-700. doi: 10.18632/oncotarget.5354.


Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment.

Gao H, Yang Z, Cao S, Xiong Y, Zhang S, Pang Z, Jiang X.

Biomaterials. 2014 Feb;35(7):2374-82. doi: 10.1016/j.biomaterials.2013.11.076. Epub 2013 Dec 15.


Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide.

Ning S, Knox SJ.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):197-203.


Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.

Hall WA, Vallera DA.

Neurosurg Focus. 2006 Apr 15;20(4):E23.


Mammary-Derived Growth Inhibitor Targeting Peptide-Modified PEG-PLA Nanoparticles for Enhanced Targeted Glioblastoma Therapy.

Feng X, Gao X, Kang T, Jiang D, Yao J, Jing Y, Song Q, Jiang X, Liang J, Chen J.

Bioconjug Chem. 2015 Aug 19;26(8):1850-61. doi: 10.1021/acs.bioconjchem.5b00379. Epub 2015 Aug 11.


A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.

Visnyei K, Onodera H, Damoiseaux R, Saigusa K, Petrosyan S, De Vries D, Ferrari D, Saxe J, Panosyan EH, Masterman-Smith M, Mottahedeh J, Bradley KA, Huang J, Sabatti C, Nakano I, Kornblum HI.

Mol Cancer Ther. 2011 Oct;10(10):1818-28. doi: 10.1158/1535-7163.MCT-11-0268. Epub 2011 Aug 22.


Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects.

Hekmatara T, Bernreuther C, Khalansky AS, Theisen A, Weissenberger J, Matschke J, Gelperina S, Kreuter J, Glatzel M.

Clin Neuropathol. 2009 May-Jun;28(3):153-64.


Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.

Redjal N, Zhu Y, Shah K.

Stem Cells. 2015 Jan;33(1):101-10. doi: 10.1002/stem.1834.

Supplemental Content

Support Center